Keros Therapeutics Inc. (KROS) News
Filter KROS News Items
KROS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest KROS News From Around the Web
Below are the latest news stories about KEROS THERAPEUTICS INC that investors may wish to consider to help them evaluate KROS as an investment opportunity.
Keros Therapeutics price target raised to $28 from $11 at Wells FargoWells Fargo raised the firm’s price target on Keros Therapeutics (KROS) to $28 from $11 and keeps an Overweight rating on the shares. The safety findings announced in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept in combination with background therapy in patients with pulmonary arterial hypertension, “basically zeroed expectations,” though cash plus pipeline is worth more than where the stock is right now, the analyst tells investors in a research note. Published first on The |
Keros Plummets 73% After Unexpected Side Effects 'Shock' Its Lead DrugKeros Therapeutics stock plummeted Thursday after the company stopped giving higher doses in a lung disease study due to side effects. |
Keros Therapeutics Prospects Still Strong Despite Cibotercept Hurdles, Wedbush SaysKeros Therapeutics' (KROS) efforts to develop new treatments for pulmonary arterial hypertension rem |
Keros shares collapse on ‘unanticipated’ setback for lung disease drugSafety concerns Keros observed in a Phase 2 trial triggered a stock selloff for what had been one of the sector’s most successful initial public offerings of the last four years, according to BioPharma Dive data. |
Keros Therapeutics Announces Update on the Phase 2 TROPOS TrialKeros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it has vo |
Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and ExpositionElritercept demonstrated a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden, with a median duration of response of 134.1 weeksDurable clinical responses were associated with improvements in patient-reported measures of fatigue in MDS patients early, and with continued improvement over timeData from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can potentially ameliorate ineffect |
Takeda licensed for anaemia therapy by Keros TherapeuticsTakeda will make an upfront payment of $200m to Keros. |
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: AnalystOn Tuesday, Takeda Pharmaceutical Company Limited (NYSE:TAK) entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (NASDAQ:KROS) to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. Elritercept is a late-stage investigational activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes and myelofibrosis. Also Read: Analyst Sees Keros Therapeutics |
Keros Therapeutics Announces Global License Agreement with Takeda to Advance ElriterceptKeros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval and commercial milestone payments with the potential to exceed $1.1 billion and tiered royalties on net sales LEXINGTON, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that a |
Keros Therapeutics Announces Participation at Upcoming Healthcare ConferencesLEXINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the followin |